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from NICE regarding inclusion of this methodology within HTA. Conclusions on the 
acceptance of this methodology by NICE cannot be made due to limited examples.
PRM214
Meta-analysis to suPPoRt technology subMissions to health 
technology assessMent authoRities: cRiticisMs by nice and 
evidence Review gRouPs in the uk
Batson S, Webb N, Greenall G
Abacus International, Oxfordshire, UK
Objectives: The quality of evidence used in manufacturers’ submissions to health 
technology assessment (HTA) bodies is an important factor for the success of tech-
nology appraisals (TA). Indirect comparisons (IC) and network meta-analyses (NMA) 
are used in health policy decisions via the clinical effectiveness evidence in HTA 
submissions to the National Institute for Health and Care Excellence (NICE). The 
aim of this study was to: (i) assess the use of ICs and NMAs in HTA submissions 
to NICE; (ii) identify criticisms of ICs and NMAs in TAs generated by NICE and the 
Evidence Review Group (ERG); (iii) provide key insights and recommendations to 
minimise criticism of an IC or NMA in future HTA submissions. MethOds: The 
NICE website was interrogated to identify both TAs and the associated ERG/final 
appraisal document reports published from January 2013 to June 2015 in any thera-
peutic setting. Results: A large proportion of the TAs analysed included ICs or 
NMAs. Common criticisms were related to the identification of data and the study 
selection for inclusion, study heterogeneity and the inadequate reporting of meth-
ods and analyses. cOnclusiOns: The majority of criticisms of evidence synthesis 
submitted to NICE were related to issues around the primary evidence included in 
the analyses rather than the statistical methods of the analyses. To avoid many of 
the criticisms identified in this study a transparent approach to the reporting of the 
ICs and NMAs (and systematic review) is recommended.
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Stephenson M1, Fleetwood K2, Yellowlees A2
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Objectives: Network meta-analysis (NMA) of clinical trial outcomes is usually 
based on Bayesian statistics and hence requires software for Monte Carlo Markov 
chain (MCMC) sampling. The most common choice of software for NMA is WinBUGS, 
in part because there is a large body of WinBUGS code for NMA in the literature; for 
example in the NICE Decision Support Unit (DSU) Technical Support Documents 
(TSD) on evidence synthesis. However, WinBUGS is slow, difficult to use, and bet-
ter, more efficient, options may be available. This project aimed to identify and 
evaluate alternatives to WinBUGS. MethOds: We identified candidate alternatives 
for evaluation via journal articles and websites. We performed an initial examina-
tion against a set of criteria including (a) compatibility with Windows (b) speed (c) 
ease of use (d) publication quality graphics (in the system or ease of linking with 
an external program such as R) (e) ability to handle large datasets within MCMC 
software and (f) cost. We ranked the candidates and then performed a validation 
of the top-ranked choice by running a set of examples found in the NICE DSU TSDs 
to ensure matching of the results. Results: We found nine potential alternatives 
to WinBUGS: OpenBUGS; JAGS; GeMTC; LaplacesDemon; Mamba; PyMC; SAS PROC 
MCMC; MCMCpack; Stan. Stan was the most promising and we tested it against a 
number of datasets used from the NICE guidance. cOnclusiOns: We found Stan, 
an open source program for Bayesian statistical inference, to be the best option for 
NMA. Stan provides an excellent balance of model flexibility, allowing for manual 
user specification, and is easily integrated with R for producing publication qual-
ity graphics. We found it straightforward to learn because it is accompanied by an 
extensive user manual and provides helpful error messages. We recommend that 
NMA practitioners should consider Stan as an alternative to WinBUGS.
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Objectives: Machine learning techniques are used for analysis of large complex 
datasets. Classification is an important part of machine learning applications, it 
defines groups within population. There are many different methods which are 
compare results to determine the best classification. In this study we aim to use 
machine learning techniques to classify OECD countries according to their health 
expenditures. MethOds: Different algorithms can be use in machine learning tech-
niques; C4.5 which is an extension version of ID.3 algorithm and CART algorithm 
are one of these most commonly use algorithms. Random Forest which constructs 
a lot of number of trees is one of another useful technique for solving both clas-
sification and regression problems. In this study we compare classification per-
formances of different decision trees (C4.5, CART) and Random Forest which was 
generated by using 50 trees. We perform this prediction model for predicting OECD 
countries health expenditures for the year 2011. We use number of independent 
variables for this prediction. These are; life expectancy at birth, number of phy-
sicians, number of hospitals, hospital aggregates, alcohol consumption, GDP per 
capita, perceived health status and immunization. We use AUC results and ROC 
curve graph for performance comparison. Results: As a result of this study it was 
seen that classification performances of machine learning techniques were good 
(AUC≥ 0.90) and Random Forest [50] classification performance results much higher 
[AUC= 0.98] than CART (0.95) and C4.5 (0.90). Decision tree graphs shows that GDP 
per capita was a variable which has more information gain for predicting health 
expenditures. cOnclusiOns: To conclude according to our knowledge this is the 
first study applied machine learning classification methods to health expenditure 
data. Future studies will compare classification performances of Random Forest 
using different types of health expenditure datasets, different predictor variables 
while increasing the number of trees in the forest.
size of an RTBCEA that balances its cost and the value of perfect information that 
would remain after its completion.
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Objectives: Quantitative analysis of spontaneous adverse drug reaction reports 
is increasingly used in drug safety research. Signals are detected by disproportion-
ality measures (DM). Different types of DMs are available: a debate is ongoing on 
which performs better. The aim was to evaluate the sensitivity on identification of 
signals with known safety profiles of incretin drugs. MethOds: Adverse Events (AE) 
reported to FDA Adverse Event Reporting System (FAERS) between 2005 and 2014 
were included. To evaluate the impact of warning actions, two separated analysis 
were conducted: restricted to the time before and after a regulatory action. We 
selected 20 AEs for each drug, half as “positive controls” (with a known causal associ-
ation from literature) and half as “negative controls” (with no evidence in literature). 
Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence 
Propagation Neural Network Analysis (BCPNN) and Gamma-Poisson Shrinker (GPS) 
were calculated on 120 combinations of AE-drugs. Correlation between sensitivity 
and number of AEs per year reported for each drug was calculated to evaluate the 
effect of number of reports on sensitivity. Results: The number of reports ana-
lyzed in 2014 was 1,934,607. After warning action, PRR showed a sensitivity of 0.42 
(0.29; 0.55), ROR 0.55 (0.42; 0.68), BCPNN 0.53 (0.40; 0.66) and GPS 0.23 (0.13; 0.36). 
Analog findings were observed before warning actions. The concordance of signals 
identification was good for all pairwise comparison between DMs (> 0.56). The cor-
relation varied among 0.49 (for PRR) and 0.82 (for ROR and BCPNN) after warning 
action. cOnclusiOns: The sensitivity of measures was low (< 0.6), without impact 
of warning actions. ROR and BCPNN showed the most elevated values of sensitivity 
not allowing to determine a clear superiority of neither frequentist nor bayesian 
DMs. As expected, the positive correlation suggests the presence of a strong impact 
on sensitivity of higher number of AEs reported.
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coRRecting foR switching to second line tReatMent in the suRvival 
analysis: an exaMPle of the use of inveRse PRobability of censoRing 
weighted analysis
Sanchez L, Luaces P, Crombet T
Center of Molecular Immunology, Havana, Cuba
Objectives: Randomized clinical trials of biological products are commonly ana-
lyzed with an intent-to-treat (ITT) approach, whereby patients are analyzed in their 
assigned treatment group regardless of actual treatment received. The ensuing 
switch to second line treatment disturbs randomization, compromising the utility 
of clinical data. The main objective of the study is to discuss how the statistical 
procedure of inverse probability of censoring weighted (IPCW) analysis may be used 
in this situation MethOds: The first step in the IPCW analysis is to predict the 
probability of switch on the basis of each patient’s baseline characteristics, such 
as age, sex, race, the time from diagnosis to randomization, and biological markers 
by fitting a logistic regression model. Finally, Overall Survival (OS) is analyzed with 
the censored data set and observations weighted by the inverse of the predicted 
probability of censoring. The method was illustrated for one clinical trial evaluating 
the effect of one monoclonal antibody combined with gemcitabine in patients with 
advanced pancreatic cancer. Results: A total of 192 patients were randomized 
(average age 63.6 ±10 years; 60% male; 69% ECOG PS 0), Of 96 patients enrolled in the 
nimotuzumab arm (OSAG), 40 patients (41.7%) switch to second line, while in the 
Placebo arm 41(42.7%) switch to the second line. The hazard ratio and 95% CI for OS 
was 0.83 (95% CI, 0.62 to 1.12) for ITT, was 0.75 (95% CI, 0.51 to 1.12) for the censored 
analysis, and for IPCW was 0.82 (95% CI, 0.67 to 0.98). cOnclusiOns: The switch 
to second line treatment affects efficacy results of the ITT analysis of the nimotu-
zumab plus Gemcitabine therapy in pancreatic cancer. Additional IPCW analysis 
indicates that the benefit of the molecular antibody, nimotuzumab, is greater than 
that reflected by the ITT estimate.
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Abacus International, Oxfordshire, UK
Objectives: Meta-analysis of survival data is most commonly performed by using 
the individual summary statistic hazard ratio (HR) from each study as an appropri-
ate measure of effect. The aim of this study was to (i) assess the literature reporting 
on the use of meta-analysis of parametric survival curves, an alternative novel 
method for the evidence synthesis of survival data; (ii) assess technology apprais-
als (TAs) submitted to the National Institute for Health and Care Excellence (NICE) 
to determine whether this novel method has been accepted within UK Health 
Technology Assessment (HTA). MethOds: Embase, Medline and the Cochrane 
Library were searched to identify publications reporting on novel statistical meth-
ods. The NICE website was interrogated to identify oncology TAs, the associated 
Evidence Review Group (ERG) and final appraisal document (FAD) as published 
between 2011 and 2014 which reported novel statistical methods. Results: Four 
publications reported on the use of meta-analysis of parametric survival curves. 
Of the most recent 60 NICE TAs, a single TA included the use of meta-analysis of 
parametric survival curves. cOnclusiOns: Meta-analysis of survival curves has 
been developed to address limitations which arise where the proportional hazards 
assumption does not hold for survival curves; however, to date the method has 
not been validated by independent statisticians and currently there is no guidance 
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publications are not available. With respect to the progress of benefit assessment and 
the subsequent price negotiation it would be helpful having alternatives with accept-
able properties in order to estimate the extent of additional benefit.
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Objectives: To use consensus-building methodologies to prioritize disease 
states for intravenous immunoglobulin (IVIG) utilization while considering dis-
ease severity and alternative therapeutic options. MethOds: A 7-member expert 
panel independently ranked 50 disease states across 2 domains: (1) Disease sever-
ity (DS) (1= immediately life-threatening, 2= life-threatening, 3= life-modifying, 
4= other) and (2) the perceived efficacy of therapeutic alternatives (TA) (1= none, 
2= low, 3= medium, 4= high). An interquartile deviation of ≤ 0.5 was used to deter-
mine consensus for disease states within each domain. Disease states reaching 
consensus across both domains were ranked according to a 4x4 algorithmic scale 
to establish priority. Results: The panel reached consensus on the severity of all 
diseases states; however, 11 of the 50 disease states did not reach consensus on 
the availability of alternative therapeutic options. No disease state was designated 
as being immediately life-threatening without an available alternative therapeu-
tic option (DS1TA1), while 3 disease states (X-linked agammaglobulinemia, com-
mon variable immunodeficiency, primary immunodeficiency with absent B-cells) 
were designated as life-threatening with no therapeutic alternatives (DS2TA1). The 
priority distribution of disorders based on the algorithm is as follows: DS1TA1= 0, 
DS1TA2= 1, DS1TA3= 1, DS1TA4= 1 DS2TA1= 3, DS2TA2= 4, DS2TA3= 3, DS2TA4= 1 
DS3TA1= 0, DS3TA2= 7, DS3TA3= 14, DS3TA4= 0 DS4TA1= 0, DS4TA2= 0, DS4TA3= 3, 
DS4TA4= 1 cOnclusiOns: The application of interquartile deviation in establishing 
consensus across two 4-point Likert scales resulted in prioritizing 80% of disease 
states where IVIG can be used. Additional consensus-building rounds will be needed 
to prioritize the remaining disease states.
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netwoRk Meta-analysis foR health technology subMissions 
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Objectives: Network meta-analysis (NMA) represents an important and develop-
ing method for Health Technology Assessment (HTA). The aim of this study was 
to review submission guidelines issued by HTA bodies worldwide and produce 
a checklist for reporting NMA within HTA submissions globally. MethOds: The 
web-based repository of country-specific pharmacoeconomic guidelines maintained 
by ISPOR was reviewed in January 2015. Guidelines from a number of countries 
providing sufficient guidance for the use of NMA in HTA submissions were iden-
tified and independently reviewed. Results: Following review of the available 
guidance from a number of countries, a single common checklist was developed. 
The checklist included recommendations relating to five main themes: data; sta-
tistical methodology; analyses performed; presentation of results; and technical 
issues. cOnclusiOns: This reporting checklist provides practical support to health 
technology manufacturers enabling them to assess the suitability of NMA reports 
in meeting the requirements of global HTA bodies. In addition, this checklist can be 
seen as a valid quality tool to critically appraise the reporting of NMAs within HTA.
ReseaRch on Methods – study design
PRM222
tRansPaRency and RePRoducibility of suPPleMentaRy seaRch 
Methods in nice single technology aPPRaisal ManufactuReR 
subMissions
Witkowski MA, Aldhouse N
Abacus International, Bicester, UK
Objectives: Systematic reviews (SRs) form an important part of National Institute 
for Health and Care Excellence (NICE) single technology appraisal (STA) manufac-
turer submissions. To minimise publication bias when conducting SRs, supple-
mentary searches should be conducted, and should follow the same principles 
of transparency and reproducibility as database searches. This study aimed to 
evaluate supplementary search methods used in NICE STA manufacturer submis-
sions. MethOds: NICE STAs published between 2011 and 2015 were reviewed. 
Supplementary search details from manufacturer submissions and related critique 
from corresponding evidence review group (ERG) reports were extracted. Searches 
were deemed reproducible if the minimum amount of information required to repro-
duce searches was reported. Results: Of 126 STAs identified, 80 were excluded: 
appraisal reviews/updates (n= 20); appraisal terminated (n= 12); no full submission 
available (n= 9); appendices (containing search methods) not published online 
(n= 39). Of 46 included manufacturer submissions, 28 reported conference searches, 
of which 24 provided enough information for searches to be reproduced. Twenty-one 
reported clinical trials registry searches, but only seven provided enough informa-
tion to reproduce these. Thirty-six reported conducting other manual searches, 
including: manufacturer internal databases (n= 24); reference lists (n= 20); regulatory 
body websites (n= 11); other websites (n= 5); internal experts (n= 2). Evidence review 
groups critiqued omission of supplementary searches in 8 of 18 submissions which 
lacked searches of conference proceedings, and in 8 of 25 submissions which did not 
report searching clinical trial registries. The evaluation methods differed between 
ERGs. cOnclusiOns: Principles of transparency and reproducibility were not fol-
PRM217
the use of PRoPensity scoRe Matching does not PRotect against 
RegRession aRtifacts (RegRession towaRds the Mean)
Caron C1, Wasser T2, Eisenberg D2
1Reading Hospital, West Reading, PA, USA, 2HealthCore Inc., Wilmington, DE, USA
Objectives: Propensity Score Matching (PSM) is a common method in many 
retrospective studies to control for differential treatments. PSM controls for vari-
ables where patients are selected for one treatment over another based on aspects 
of their care that are unknown to the researcher or not a part of the study. This 
study uses simulated data comparing two cohorts within a population treated 
for a common psychiatric disorder. Data are analyzed to determine if regression 
artifacts (RA) are present in the data, uncontrolled by PSM. RA in this context are 
Type I errors. MethOds: Variables commonly used to diagnose patients with 
Major Depression were simulated: Age, Gender, Ethnicity, Global Assessment of 
Functioning, Beck Depression and Beck Anxiety scores. Distributions of N= 100,000 
were simulated for each variable using population values. From these distribu-
tions, samples of n= 100, n= 250 and n= 500 were drawn based on typical values 
that would be seen in a patient with Major Depression. The outcome measure 
Dependent Variable was the score on the Beck Depression scale, using success of 
treatment values from 10-15 percent, and correlated with the pretest score using 
Chomsky’s decomposition. PSM was used on a ratio of 1:1. Analysis methods were 
group and paired t-tests as well as a difference in difference analysis at the end of 
the study. Results: Type I error occurred in each simulation and were correlated 
with sample size. RA, leading to Type I error were more common at lower sample 
sizes, in excess of 70%, to a minimum of 54% for n= 500. cOnclusiOns: This study 
demonstrates that RA occur in basic experiments designed to specify treatment 
effects. Researchers who use PSM methods need to be aware of situations where 
RA are likely to occur. Standard statistical controls for RA are being tested to see if 
they correct for RA and Type I error when PSM is used.
PRM218
aPPlication of siMPle iMPutation techniques foR Missing PaiRwise 
contRasts fRoM Multi-aRM tRials when using fRequentist netwoRk 
Meta analysis
Petto H1, Brnabic A2, Kadziola Z1, Belger M3
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Company Ltd, Windlesham, UK
Objectives: When conducting frequentist (fixed effects or random effects) network 
meta-analysis (NMA), input data is usually required in contrast form. In practice, 
multiple-arm trials are quite common and results for only the contrast relative to 
one treatment group are presented. However, some frequentist NMA require all 
possible pairwise treatment effects and standard errors combinations. While the 
missing effect sizes can still be directly derived, additional assumptions about co-
variances are needed to calculate standard errors. MethOds: Simple imputation 
techniques are used for substituting the standard errors of the missing comparisons 
and this has been applied to both simulated data as well as a real world data exam-
ple. After imputation data is analyzed using standard frequentist NMA, incorporat-
ing multi arm studies by the method described in Rücker (2015). Results: We derive 
simple imputations techniques by (1) assuming independence between contrasts, 
(2) estimating missing co-variances from the available contrasts in the multi arm 
trials and (3) from the other two arm studies in the network. Comparable results 
to networks including all pairwise contrasts can be obtained, especially if only few 
contrasts are missing in multi arm studies and if variances of the comparisons are 
not too different. In the first case, even (1) can give acceptable results. If variances 
differ, but are similar to that from two arm studies then (3) might be preferable over 
(2). cOnclusiOns: Our results suggests that from a practical point of view, simple 
imputation techniques might be useful tools for incorporating multi arm trials with 
incomplete pairwise contrasts into frequentist NMA, although limitations need to 
be carefully considered. Rücker G: Network meta-analysis, electrical networks and 
graph theory. Research Synthesis Methods, 2012, 3, 312–324.
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Kühnast S1, Schiffner-Rohe J2, Rahnenführer J1, Leverkus F2
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Germany
Objectives: With the Act on the Reform of the Market for Medicinal Products 
(AMNOG) in Germany, pharmaceutical entrepreneurs must submit a dossier dem-
onstrating additional benefit of a new drug compared to an appropriate comparator. 
Underlying evidence was planned for registration purposes and therefore often does 
not meet the appropriate comparator as defined by the Federal Joint Committee 
(G-BA). For this reason AMNOG allows indirect comparisons (ICs) to assess the 
extent of additional benefit. This study evaluates the applicability of available IC 
methods in several situations common to benefit assessment in oncological indi-
cations. MethOds: An extensive literature search on available statistical methods 
for performing ICs is performed. Additionally, benefit dossiers containing ICs are 
analyzed regarding the applied methodology. We use simulation studies to evaluate 
and compare adjusted (Bucher) and unadjusted methods regarding their properties 
under different circumstances. Results: Adjusted ICs are deemed to be “state of the 
art”. Due to their requirements they are, nevertheless, often not applicable. In most 
cases reasons are lacking comparability of the trials, e.g. concerning the common 
comparator, the study population and the study design.Simulations of Hazard Ratios 
for endpoints overall survival and progression free survival were performed consider-
ing various “extents of additional benefit” according to IQWiG criteria. Starting with a 
setting of identical studies we stepwise modified study population and various attrib-
utes in study design. Finally the common comparator was omitted. Discrepancies 
between ICs and true values are compared graphically and on the basis of statistical 
measures. cOnclusiOns: ICs imply a set of requirements to be able to derive valid 
statements. Prerequisites for adjusted ICs are often not met as necessary studies and 
